Lapatinib, marketed under the brand name Tykerb, is an oral targeted therapy used in the treatment of certain types of cancer. It belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). Lapatinib works by inhibiting the activity of two proteins, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), which are involved in the growth and spread of cancer cells.
